<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016596</url>
  </required_header>
  <id_info>
    <org_study_id>NL75915.041.21</org_study_id>
    <nct_id>NCT05016596</nct_id>
  </id_info>
  <brief_title>Postprandial Lipids in IBS and Nutritional Treatment</brief_title>
  <acronym>PLINT</acronym>
  <official_title>Postprandial Lipids in IBS and Nutritional Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Economic Affairs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naturex SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nexira</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wecare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roquette Freres</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ingredion Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ingredia S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Darling</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winclove Probiotics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioiberica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable Bowel Syndrome (IBS) is a disease that affects a large number of people. Adequate&#xD;
      treatment is difficult, partially due to the heterogeneity of the patients and the&#xD;
      complicated pathology in which not all mechanisms are understood. Based on literature and in&#xD;
      vitro screening within the public private IBSQUtrition consortium project, a turmeric&#xD;
      supplement was selected for in vivo validation of its potential beneficial effects on&#xD;
      fat-induced intestinal barrier disruption as measured with LPS translocation in IBS patients&#xD;
      with a diarrhea-predominant subtype (IBS-D).&#xD;
&#xD;
      The primary objective of this study is to determine the effect of turmeric supplementation on&#xD;
      LPS translocation in IBS-D patients after a high-fat challenge. The secondary objective of&#xD;
      this study is to determine the effect of turmeric supplementation on gastrointestinal&#xD;
      complaints and LPS-related biomarkers in IBS-D patients after a high-fat challenge.&#xD;
&#xD;
      In this double-blind, randomized, placebo-controlled cross-over trial 20 adult (18-70 yrs)&#xD;
      IBS-D patients will be included.&#xD;
&#xD;
      Study participants have to invest about 16 hours of their time in this study. They will visit&#xD;
      the research facility three times. The risks for participation are very small if not&#xD;
      negligible. Consumption of high amounts of saturated fat may cause some gastro-intestinal&#xD;
      discomfort. Blood sampling will be performed via a cannula and the insertion can be a bit&#xD;
      painful and may cause a bruise. The amount of blood that is drawn from participants is&#xD;
      relatively small and within acceptable limits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LPS_B</measure>
    <time_frame>Baseline</time_frame>
    <description>LPS in venous blood samples collected at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LBP_1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>LBP in venous blood samples collected after high-fat shake consumption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS_2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>LPS in venous blood samples collected after high-fat shake consumption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS_3</measure>
    <time_frame>3 hours post ingestion</time_frame>
    <description>LPS in venous blood samples collected after high-fat shake consumption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS_4</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>LPS in venous blood samples collected after high-fat shake consumption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS_5</measure>
    <time_frame>5 hours post ingestion</time_frame>
    <description>LPS in venous blood samples collected after high-fat shake consumption.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ApoB48_B</measure>
    <time_frame>Baseline</time_frame>
    <description>ApoB48 at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPB_B</measure>
    <time_frame>Baseline</time_frame>
    <description>LPB at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_B</measure>
    <time_frame>Baseline</time_frame>
    <description>sCD14 at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB48_1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>ApoB48 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPB_1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>LPB after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>sCD14 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB48_2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>ApoB48 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPB_2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>LPB after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>sCD14 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB48_3</measure>
    <time_frame>3 hours post ingestion</time_frame>
    <description>ApoB48 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPB_3</measure>
    <time_frame>3 hours post ingestion</time_frame>
    <description>LPB after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_3</measure>
    <time_frame>3 hours post ingestion</time_frame>
    <description>sCD14 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB48_4</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>ApoB48 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPB_4</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>LPB after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_4</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>sCD14 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoB48_5</measure>
    <time_frame>5 hours post ingestion</time_frame>
    <description>ApoB48 after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPB_5</measure>
    <time_frame>5 hours post ingestion</time_frame>
    <description>LPB after high-fat shake consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_5</measure>
    <time_frame>5 hours post ingestion</time_frame>
    <description>sCD14 after high-fat shake consumption</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Age</measure>
    <time_frame>Baseline</time_frame>
    <description>Age</description>
  </other_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>Baseline</time_frame>
    <description>BMI</description>
  </other_outcome>
  <other_outcome>
    <measure>Gender</measure>
    <time_frame>Baseline</time_frame>
    <description>Gender</description>
  </other_outcome>
  <other_outcome>
    <measure>GI complaints</measure>
    <time_frame>Baseline</time_frame>
    <description>GI complaints</description>
  </other_outcome>
  <other_outcome>
    <measure>IBS-related complaints (IBS-SSS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Severity of IBS-related complaints (IBS-SSS), single score</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Stool frequency on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Stool frequency on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Stool frequency on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency-T</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Stool frequency on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency+1</measure>
    <time_frame>24hr</time_frame>
    <description>Stool frequency on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency+2</measure>
    <time_frame>48hr</time_frame>
    <description>Stool frequency on test day +2</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool consistency-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Stool consistency (Bristol stool chart) on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool consistency-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Stool consistency (Bristol stool chart) on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool consistency-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Stool consistency (Bristol stool chart) on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool consistency-T</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Stool consistency (Bristol stool chart) on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool consistency+1</measure>
    <time_frame>24hr</time_frame>
    <description>Stool consistency (Bristol stool chart) on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool consistency+2</measure>
    <time_frame>48hr</time_frame>
    <description>Stool consistency (Bristol stool chart) on test day +2</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal pain-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Abdominal pain (Likert scale 0-10) on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal pain-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Abdominal pain (Likert scale 0-10) on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal pain-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Abdominal pain (Likert scale 0-10) on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal pain-T</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Abdominal pain (Likert scale 0-10) on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal pain+1</measure>
    <time_frame>24hr</time_frame>
    <description>Abdominal pain (Likert scale 0-10) on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Abdominal pain+2</measure>
    <time_frame>48hr</time_frame>
    <description>Abdominal pain (Likert scale 0-10) on test day +2</description>
  </other_outcome>
  <other_outcome>
    <measure>Bloating-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Bloating (Likert scale 0-10) on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Bloating-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Bloating (Likert scale 0-10) on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Bloating-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Bloating (Likert scale 0-10) on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Bloating-T</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Bloating (Likert scale 0-10) on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Bloating+1</measure>
    <time_frame>24hr</time_frame>
    <description>Bloating (Likert scale 0-10) on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Bloating+2</measure>
    <time_frame>48hr</time_frame>
    <description>Bloating (Likert scale 0-10) on test day +2</description>
  </other_outcome>
  <other_outcome>
    <measure>Flatulence-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Flatulence (Likert scale 0-10) on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Flatulence-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Flatulence (Likert scale 0-10) on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Flatulence-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Flatulence (Likert scale 0-10) on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Flatulence-T</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Flatulence (Likert scale 0-10) on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Flatulence+1</measure>
    <time_frame>24hr</time_frame>
    <description>Flatulence (Likert scale 0-10) on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Flatulence+2</measure>
    <time_frame>48hr</time_frame>
    <description>Flatulence (Likert scale 0-10) on test day +2</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Nausea (Likert scale 0-10) on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Nausea (Likert scale 0-10) on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Nausea (Likert scale 0-10) on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea-T</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Nausea (Likert scale 0-10) on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea+1</measure>
    <time_frame>24hr</time_frame>
    <description>Nausea (Likert scale 0-10) on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea+2</measure>
    <time_frame>48hr</time_frame>
    <description>Nausea (Likert scale 0-10) on test day +2</description>
  </other_outcome>
  <other_outcome>
    <measure>Heartburn-3</measure>
    <time_frame>-72hr</time_frame>
    <description>Heartburn (Likert scale 0-10) on test day -3</description>
  </other_outcome>
  <other_outcome>
    <measure>Heartburn-2</measure>
    <time_frame>-48hr</time_frame>
    <description>Heartburn (Likert scale 0-10) on test day -2</description>
  </other_outcome>
  <other_outcome>
    <measure>Heartburn-1</measure>
    <time_frame>-24hr</time_frame>
    <description>Heartburn (Likert scale 0-10) on test day -1</description>
  </other_outcome>
  <other_outcome>
    <measure>Heartburn</measure>
    <time_frame>Testday (0hr)</time_frame>
    <description>Heartburn (Likert scale 0-10) on test day</description>
  </other_outcome>
  <other_outcome>
    <measure>Heartburn+1</measure>
    <time_frame>24hr</time_frame>
    <description>Heartburn (Likert scale 0-10) on test day +1</description>
  </other_outcome>
  <other_outcome>
    <measure>Heartburn+2</measure>
    <time_frame>48hr</time_frame>
    <description>Heartburn (Likert scale 0-10) on test day +2</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acacia gum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>turmeric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Turmeric supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>turmeric</intervention_name>
    <description>Turmeric supplement</description>
    <arm_group_label>turmeric</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IBS patients that meet the Rome IV criteria + additional criteria specific for the&#xD;
             diarrhea-predominant subtype, based on the most frequent self-reported stool types&#xD;
             using the Bristol stool chart&#xD;
&#xD;
          -  Male and female adults, aged 18-70 years;&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5 and 30 kg/m2;&#xD;
&#xD;
          -  Willing to keep a stable dietary pattern throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having a disease that may interfere with the outcomes of this study, such as a known&#xD;
             autonomic disorder, inflammatory bowel disease, coeliac disease, cancer, dialysis&#xD;
             patients, chronic kidney failure, depression or hypothyroidism.&#xD;
&#xD;
          -  History of intestinal surgery (excluding appendectomy or cholecystectomy) or&#xD;
             endometriosis.&#xD;
&#xD;
          -  Use of medication that can interfere with the study outcomes, including codeine and&#xD;
             antibiotics, as judged by the medical supervisor.&#xD;
&#xD;
          -  Use of anticoagulants (as curcumin has inhibitory effects on platelet aggregation).&#xD;
&#xD;
          -  Use of prebiotics and/or probiotics (should be stopped 4 weeks before the start of the&#xD;
             study) and infrequent use of other supplements dedicated to bowel function&#xD;
             improvements.&#xD;
&#xD;
          -  Having swallowing problems with pills/capsules.&#xD;
&#xD;
          -  Having a cow's milk allergy or other food allergies.&#xD;
&#xD;
          -  If applicable: currently pregnant or breastfeeding, or intending to become pregnant&#xD;
             during the study.&#xD;
&#xD;
          -  Participation in another clinical trial at the same time.&#xD;
&#xD;
          -  Student or employee working at Food, Health and Consumer Research from Food and&#xD;
             Biobased Research, or Department of Human Nutrition &amp; Health, Wageningen University.&#xD;
&#xD;
          -  Alcohol intake ≥ 14 (women) or ≥ 28 (men) glasses of alcoholic beverages per week.&#xD;
&#xD;
          -  Smoking and abuse of illicit drugs, soft drugs, and/or nitrous oxide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University and Research</investigator_affiliation>
    <investigator_full_name>Diederik Esser</investigator_full_name>
    <investigator_title>Clinical Trial Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

